A gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma. This discovery could lead to new therapies for this currently hard-to-treat tumor.
“We were delighted to find that the same BRAF mutation previously described in melanomas and other brain tumors appears to be driving the growth of these tumors,” said Priscilla Brastianos, MD, of the Massachusetts General Hospital Cancer Center and the Broad Institute in Boston. “BRAF inhibitors have shown great promise in treating patients with other tumors with this mutation, and we hope to quickly evaluate these drugs in patients with papillary craniopharyngioma in hopes of reducing the serious consequences of this disease.”
Craniopharyngiomas arise at the base of the skull adjacent to the pituitary gland, the hypothalamus, and other critical brain structures. Although they are not inherently aggressive tumors, because of their location, they can significantly compromise vision and other neurologic and endocrine functions. The tumors cling to brain structures, usually making surgical removal challenging, and radiation therapy can cause vascular abnormalities or other tumors.
The two subtypes of craniopharyngiomas are adamantinomatous tumors, which are more common in children, and papillary tumors, which are usually seen in adults. Recent studies have associated mutations in the oncogene CTNNB1 with adamantinomatous tumors, but prior to this study, no information was available about the molecular drivers of the papillary subtype.
In their search for possible mutations associated with papillary tumors, the research team first performed whole exome sequencing of 15 craniopharyngiomas: 12 adamantinomatous and 3 papillary. Among adamantinomatous tumors, the previously identified CTNNB1 mutation was found in 11 of the 12 samples; and for the first time, the known tumor-associated BRAF mutation was identified in all three papillary tumors.
The researchers followed that finding with a targeted genotyping of tumor samples from an additional 95 patients. Among tested papillary tumors, 94% had the BRAF mutation, whereas 96% of the adamantinomatous tumors had the CTNNB1 mutation. The investigators also confirmed that both types of tumors had very few other mutations and that the BRAF or CTNNB1 mutations were present in all tumor cells, suggesting they occurred early in tumor development. These findings were published in Nature Genetics (2014; doi:10.1038/ng.2868).
“There are currently no medical therapies available for craniopharyngiomas, but potent compounds that block BRAF signaling are in hand. So we are very hopeful that these targeted therapies can drastically alter the management of these tumors,” said Sandro Santagata, MD, PhD, of Brigham and Women’s Hospital in Boston, Massachusetts. “Inhibitors of the signaling pathway controlled by CTNNB1 that are currently in clinical trials should be investigated for adamantinomatous tumors, and we’re planning to evaluate the BRAF inhibitors that have had promising results against melanoma for treatment of papillary craniopharyngiomas.”